Is use of a long-term proton pump inhibitor or histamine-2 receptor antagonist a risk factor for iron-deficiency anaemia in Taiwan? A neglected clinical drug-drug interaction
Family Practice · 2025
DOI: 10.1093/fampra/cmad090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Family Practice, 2025. Verfasst von Yi-Ting Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Histamine H2 Antagonists, Anemia, Iron-Deficiency. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Science and Technology Council.
Abstract (Originalsprache)
Background
Proton pump inhibitors (PPIs) and histamine-2 receptor (H2) antagonists change the gastric pH and reduce the intestinal absorption of nonheme iron. Case reports and case-control studies have demonstrated that absorption of iron is affected by gastric acidity, but the clinical importance of these drug-drug interactions has remained uncertain.
Objectives
The present case-control study employed 2 million longitudinal claims in 2011–2018 in the Taiwan National Health Insurance Research Database to investigate the impact of PPIs/H2 antagonists on the occurrence of iron-deficiency anaemia (IDA).
Methods
The present study retrospectively compared exposure to PPIs/H2 antagonists for 1 year among 5,326 cases with IDA and 21,304 matched controls. The postdiagnosis prescribing pattern was also calculated to understand current practice.
Results
Long-term (≥2 month) use of PPIs/H2 antagonists resulted in a higher risk of developing IDA than noncontinuous use/nonuse of those drugs (adjusted odds ratio [aOR] = 2.36, 95% confidence interval [CI] = 1.94–2.86, P < 0.001). There were significant changes in the postdiagnosis prescribing patterns of PPIs/H2 antagonists. The risk of developing IDA remained significant in the female subgroup (aOR = 2.16, 95% CI = 1.73–2.70, P < 0.001) and was even more prominent in those aged ≥ 50 years (aOR = 2.68, 95% CI = 1.94–3.70, P < 0.05).
Conclusions
This study found that long-term use of PPIs/H2 antagonists increased the risk of developing IDA, and there was strong evidence of prescription pattern adjustments postdiagnosis. Physicians and pharmacists should be aware of this risk when patients are expected to take or have been taking PPIs/H2 antagonists for the long term.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
- Department of Pharmacy, Taipei Municipal Wan-Fang Hospital, Taipei, Taiwan.
ORCID-Profile: Yi-Ting Wu, Ya-Ting Lu, Chao-Yu Chu, Horng-Jiun Chao, Li-Na Kuo, Kuei-Ju Cheng, Hsiang-Yin Chen
Förderung
- National Science and Technology Council
Zitieren
APA
Wu, Y. T., Lu, Y. T., Chu, C. Y., Chao, H. J., Kuo, L. N., Cheng, K. J., & Chen, H. Y. (2025). Is use of a long-term proton pump inhibitor or histamine-2 receptor antagonist a risk factor for iron-deficiency anaemia in Taiwan? A neglected clinical drug-drug interaction. Family Practice. https://doi.org/10.1093/fampra/cmad090
Vancouver
Wu YT, Lu YT, Chu CY, Chao HJ, Kuo LN, Cheng KJ, et al. Is use of a long-term proton pump inhibitor or histamine-2 receptor antagonist a risk factor for iron-deficiency anaemia in Taiwan? A neglected clinical drug-drug interaction. Family Practice. 2025. doi:10.1093/fampra/cmad090
BibTeX
@article{Wu2025,
author = {Wu, Yi-Ting and Lu, Ya-Ting and Chu, Chao-Yu and Chao, Horng-Jiun and Kuo, Li-Na and Cheng, Kuei-Ju and Chen, Hsiang-Yin},
title = {Is use of a long-term proton pump inhibitor or histamine-2 receptor antagonist a risk factor for iron-deficiency anaemia in Taiwan? A neglected clinical drug-drug interaction},
journal = {Family Practice},
year = {2025},
doi = {10.1093/fampra/cmad090}
}
EUVIMED